Skip to main content

Immuno-oncology and immunotherapy Part C

  • 1st Edition, Volume 191 - January 15, 2025
  • Editors: Lorenzo Galluzzi, Norma Bloy, Maud Charpentier
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 4 4 3 - 2 9 6 2 0 - 8
  • eBook ISBN:
    9 7 8 - 0 - 4 4 3 - 2 9 6 2 1 - 5

Immuno-oncology and immunotherapy, Part C, Volume 191 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting c… Read more

Immuno-oncology and immunotherapy Part C

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Image of books

Institutional subscription on ScienceDirect

Request a sales quote
Immuno-oncology and immunotherapy, Part C, Volume 191 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Extraction and quantification of histones from human cells, Expression and characterization of Phosphatidylserine-targeting antibodies for biochemical and therapeutic applications, ILC differentiation from HSCs in vitro, Methods to expand human Treg cells and assay their function, Monitoring rapid activation of human gamma/delta T cells by multicolor flow cytometry, Methods to induce T cell exhaustion in vitro, Ex vivo assessment of human neutrophil motility and migration, and much more.

Additional chapters focus on Flow cytometry-based monitoring of myeloid-derived suppressor cells in the peripheral blood of patients with solid tumors, Deciphering human blood and tumor neutrophil heterogeneity: Methods for isolation and assessing suppression of T-cell proliferation, Splenocyte anticancer citotoxicity assessment after prophylactic vaccination or drug treatment of tumor-bearing mice, Therapeutic treatment of tumor-bearing mice with drug-killed cancer cells: a method to confirm immunogenic cell death and assess its therapeutic effectiveness, and much more.